scispace - formally typeset
T

Timothy C. Johnstone

Researcher at University of California, Santa Cruz

Publications -  80
Citations -  6024

Timothy C. Johnstone is an academic researcher from University of California, Santa Cruz. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 31, co-authored 70 publications receiving 4938 citations. Previous affiliations of Timothy C. Johnstone include Massachusetts Institute of Technology & University of Toronto.

Papers
More filters
Journal ArticleDOI

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

TL;DR: Recently, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs as mentioned in this paper.
Journal ArticleDOI

Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery

TL;DR: A series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery was presented in this article. But, their performance was limited by the fact that the axial ligands of the prodrug were asymmetrically functionalized so as to mimic the overall features of a fatty acid.
Journal ArticleDOI

Beyond iron: non-classical biological functions of bacterial siderophores

TL;DR: An exposition of past and current work into non-classical functions of siderophores is presented and the directions in which this research is headed are highlighted.
Journal Article

Understanding and Improving Platinum Anticancer Drugs – Phenanthriplatin

TL;DR: Pricker et al. as discussed by the authors reviewed some of the recent work on phenanthriplatin, a cisplatin derivative in which a chloride ion is replaced by phenanthridine, and one of its analogues, the previously reported pyriaplatin.

Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery

TL;DR: A series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery are presented, and it is suggested that the prodrug is buried below the surface of the protein.